FedMed to Offer Pacific Edges’ Cxbladder [Professional Services Close – Up]

Pacific Edge, a cancer diagnostic company, has signed an agreement with FedMed, a provider network in the United States, to make Cxbladder available.

In a release on Oct. 16, the Company said that the agreement with FedMed Inc has been finalised with Pacific Edge's subsidiary in the USA, Pacific Edge Diagnostics USA.

The agreement provides FedMed's contracted insurance carriers, third party administrators, health and welfare funds, and self- insured health plans with access to Cxbladder.

Pacific Edge Chief Executive Officer, David Darling said, "This agreement is further recognition for Cxbladder and its ability to enable clinicians to detect urothelial carcinomas, including cancers of the bladder, from a small urine sample. Combined with the simple to use Urine Sampling System, the Cxbladder technology makes detection of bladder cancer a more effective proposition for both clinicians and patients alike."

CEO of PED USA Jackie Walker said, "We are enthusiastic about the continued market acceptance of our Cxbladder test for bladder cancer detection.The Cxbladder proposition as a quick, cost effective, non- invasive and highly accurate cancer detection test is particularly appealing to US healthcare professionals, patients, and insurers who can see its positive benefits. This is a big step forward for Cxbladder and further supports our direct marketing efforts to clinicians and cancer patients."

"The building blocks are in place, sales people are active in the market and Pacific Edge remains confident of reaching its target of revenues of $100 million from Cxbladder sales in the USA within five trading years," Darling said.

Cxbladder is a diagnostic test that enables the non-invasive detection of bladder cancer from a small volume of urine.

((Comments on this story may be sent to [email protected]))